Lv4
650 积分 2022-12-08 加入
Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial
1个月前
已完结
The aetiology of breast cancer subtypes: results from the Million Women Study
1个月前
已完结
Pembrolizumab for Early Triple-Negative Breast Cancer
2个月前
已完结
皖公网安备34019202002308
